Form 4: Bicara Therapeutics Director Nils Lonberg Acquires Stock Options

Director Nils Lonberg acquired 23,746 stock options in Bicara Therapeutics on September 12, 2024.

Summary

• On September 12, 2024, Nils Lonberg, a director of Bicara Therapeutics Inc. [BCAX], acquired 23,746 stock options.
• The exercise price of these options is $18.
• The options vest upon the earlier of August 16, 2025, or the date of the next Annual Meeting of Stockholders, contingent on continued service.
• The options expire on September 12, 2034.
• Following the transaction, Lonberg directly owns 23,746 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options to a director is a common practice and generally viewed as a positive sign of alignment with shareholder interests.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotech companies.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparable companies like Iovance Biotherapeutics and Adaptimmune Therapeutics also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially driving long-term value creation.

Key Dates